PURPOSE: In vivo imaging of the spread of oncolytic viruses using the Na/I symporter (NIS) has been proposed. Here, we assessed whether the presence of NIS in the viral genome affects the therapeutic efficacy of the oncolytic adenovirus dl922-947 following intraperitoneal administration, in a mouse model of peritoneal ovarian carcinoma. METHODS: We generated AdAM7, a dl922-947 oncolytic adenovirus encoding the NIS coding sequence. Iodide uptake, NIS expression, infectivity and cell-killing activity of AdAM7, as well as that of relevant controls, were determined in vitro. In vivo, the propagation of this virus in the peritoneal cavity of tumour-bearing mice was determined using SPECT/CT imaging and its therapeutic efficacy was evaluated. RESULTS: In vitro infection of ovarian carcinoma IGROV-1 cells with ADAM7 led to functional expression of NIS. However, the insertion of NIS into the viral genome resulted in a loss of efficacy of the virus in terms of replication and cytotoxicity. In vivo, on SPECT/CT imaging AdAM7 was only detectable in the peritoneal cavity of animals bearing peritoneal ovarian tumours for up to 5 days after intraperitoneal administration. Therapeutic experiments in vivo demonstrated that AdAM7 is as potent as its NIS-negative counterpart. CONCLUSION: This study demonstrated that despite the detrimental effect observed in vitro, insertion of the reporter gene NIS in an oncolytic adenovirus did not affect its therapeutic efficacy in vivo. We conclude that NIS is a highly relevant reporter gene to monitor the fate of oncolytic adenovectors in live subjects.
PURPOSE: In vivo imaging of the spread of oncolytic viruses using the Na/I symporter (NIS) has been proposed. Here, we assessed whether the presence of NIS in the viral genome affects the therapeutic efficacy of the oncolytic adenovirus dl922-947 following intraperitoneal administration, in a mouse model of peritoneal ovarian carcinoma. METHODS: We generated AdAM7, a dl922-947 oncolytic adenovirus encoding the NIS coding sequence. Iodide uptake, NIS expression, infectivity and cell-killing activity of AdAM7, as well as that of relevant controls, were determined in vitro. In vivo, the propagation of this virus in the peritoneal cavity of tumour-bearing mice was determined using SPECT/CT imaging and its therapeutic efficacy was evaluated. RESULTS: In vitro infection of ovarian carcinoma IGROV-1 cells with ADAM7 led to functional expression of NIS. However, the insertion of NIS into the viral genome resulted in a loss of efficacy of the virus in terms of replication and cytotoxicity. In vivo, on SPECT/CT imaging AdAM7 was only detectable in the peritoneal cavity of animals bearing peritoneal ovarian tumours for up to 5 days after intraperitoneal administration. Therapeutic experiments in vivo demonstrated that AdAM7 is as potent as its NIS-negative counterpart. CONCLUSION: This study demonstrated that despite the detrimental effect observed in vitro, insertion of the reporter gene NIS in an oncolytic adenovirus did not affect its therapeutic efficacy in vivo. We conclude that NIS is a highly relevant reporter gene to monitor the fate of oncolytic adenovectors in live subjects.
Authors: A Boland; M Ricard; P Opolon; J M Bidart; P Yeh; S Filetti; M Schlumberger; M Perricaudet Journal: Cancer Res Date: 2000-07-01 Impact factor: 12.701
Authors: Inge Peerlinck; Andrew Merron; Patrick Baril; Sophie Conchon; Pilar Martin-Duque; Cécilia Hindorf; Jerome Burnet; Miguel Quintanilla; Mohan Hingorani; Richard Iggo; Nick R Lemoine; Kevin Harrington; Georges Vassaux Journal: Clin Cancer Res Date: 2009-10-27 Impact factor: 12.531
Authors: A Merron; I Peerlinck; P Martin-Duque; J Burnet; M Quintanilla; S Mather; M Hingorani; K Harrington; R Iggo; G Vassaux Journal: Gene Ther Date: 2007-10-25 Impact factor: 5.250
Authors: David Dingli; Kah-Whye Peng; Mary E Harvey; Philip R Greipp; Michael K O'Connor; Roberto Cattaneo; John C Morris; Stephen J Russell Journal: Blood Date: 2003-11-06 Impact factor: 22.113
Authors: Lynda Coughlan; Sabari Vallath; Antonio Saha; Magdalena Flak; Iain A McNeish; Georges Vassaux; John F Marshall; Ian R Hart; Gareth J Thomas Journal: J Virol Date: 2009-04-15 Impact factor: 5.103
Authors: Thomas Groot-Wassink; Eric O Aboagye; Matthias Glaser; Nicholas R Lemoine; Georges Vassaux Journal: Hum Gene Ther Date: 2002-09-20 Impact factor: 5.695
Authors: Maria Rajecki; Aki Kangasmäki; Leena Laasonen; Sophie Escutenaire; Tanja Hakkarainen; Jarmo Haukka; Ari Ristimäki; Kalevi Kairemo; Lotta Kangasniemi; Timo Kiljunen; Timo Joensuu; Sari Pesonen; Akseli Hemminki Journal: Mol Ther Date: 2011-04 Impact factor: 11.454
Authors: Sarah Urnauer; Stephan Morys; Ana Krhac Levacic; Andrea M Müller; Christina Schug; Kathrin A Schmohl; Nathalie Schwenk; Christian Zach; Janette Carlsen; Peter Bartenstein; Ernst Wagner; Christine Spitzweg Journal: Mol Ther Date: 2016-05-09 Impact factor: 11.454
Authors: M Veronica Lopez; Angel A Rivera; Diego L Viale; Lorena Benedetti; Nicasio Cuneo; Kristopher J Kimball; Minghui Wang; Joanne T Douglas; Zeng B Zhu; Alicia I Bravo; Manuel Gidekel; Ronald D Alvarez; David T Curiel; Osvaldo L Podhajcer Journal: Mol Ther Date: 2012-09-04 Impact factor: 11.454
Authors: Maria Rajecki; Mirkka Sarparanta; Tanja Hakkarainen; Mikko Tenhunen; Iulia Diaconu; Venla Kuhmonen; Kalevi Kairemo; Anna Kanerva; Anu J Airaksinen; Akseli Hemminki Journal: PLoS One Date: 2012-03-07 Impact factor: 3.240
Authors: Béatrice Cambien; Philippe R Franken; Audrey Lamit; Thibault Mauxion; Peggy Richard-Fiardo; Julien Guglielmi; Lydie Crescence; Bernard Mari; Thierry Pourcher; Jacques Darcourt; Manuel Bardiès; Georges Vassaux Journal: PLoS One Date: 2014-03-24 Impact factor: 3.240
Authors: Monique R Bernsen; Pieter E B Vaissier; Roel Van Holen; Jan Booij; Freek J Beekman; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2014-05 Impact factor: 9.236